HDAC8 and nonpapillary renal cell carcinoma: Taken together, these results indicate that the constructed HDAC8‐in‐PROTAC optimizes the effects of HDAC8 inhibitors and enhances the sensitivity of ccRCC to TKIs (Figure 8M).